Entero Therapeutics (ENTO) Short Interest Ratio & Short Volume

Short interest is the volume of Entero Therapeutics shares that have been sold short but have not yet been covered or closed out. As of August 31st, investors have sold 76,400 shares of ENTO short. 2.42% of Entero Therapeutics' shares are currently sold short. Learn More on Entero Therapeutics' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.42% of Entero Therapeutics' floating shares are currently sold short.

Entero Therapeutics saw a drop in short interest in August. As of August 31st, there was short interest totaling 76,400 shares, a drop of 80.6% from the previous total of 393,700 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Entero Therapeutics currently has issued a total of 2,475,000 shares. Some of Entero Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Entero Therapeutics currently has a public float of 3,160,000 shares.

2.42% of Entero Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Entero Therapeutics: Mainz Biomed (2.39%), Mustang Bio, Inc. (1.92%), Ainos, Inc. (14.20%), Protagenic Therapeutics, Inc. (0.29%), Lipella Pharmaceuticals Inc. (4.38%), MyMD Pharmaceuticals, Inc. (11.82%), Sonnet BioTherapeutics Holdings, Inc. (0.90%), Onconetix, Inc. (2.49%), Petros Pharmaceuticals, Inc. (3.52%), Ensysce Biosciences, Inc. (6.26%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.11 billion), Canadian Natural Resources Limited ($4.04 billion), Suncor Energy Inc. ($3.19 billion), Aptiv PLC ($2.56 billion), Paychex, Inc. ($2.48 billion), Cencora, Inc. ($2.28 billion), Onsemi ($2.08 billion), Moderna, Inc. ($1.98 billion), Tractor Supply ($1.93 billion), and International Paper ($1.93 billion). View all of the most shorted stocks.

Short selling ENTO is an investing strategy that aims to generate trading profit from Entero Therapeutics as its price is falling. ENTO shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Entero Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ENTO, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ENTO, twice per month. The most recent reporting period available is August, 31 2024.